Skip to main content
HPB : The Official Journal of the International Hepato Pancreato Biliary Association logoLink to HPB : The Official Journal of the International Hepato Pancreato Biliary Association
. 2013 Dec 6;16(6):575–581. doi: 10.1111/hpb.12193

Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin

In Woong Han 1,*, Jin-Young Jang 2,*, Kyoung Bun Lee 3, Mee Joo Kang 2, Wooil Kwon 2, Jae Woo Park 2, Ye Rim Chang 2, Sun-Whe Kim 2
PMCID: PMC4048079  PMID: 24308425

Abstract

Background

The fate of a microscopic positive ductal margin (MPDM) of extrahepatic bile duct (EHBD) cancer is unclear. The purpose of this study was to analyse the clinicopathological features of EHBD cancer with MPDM and to identify the prognostic factors associated with survival.

Methods

Between 1995 and 2007, a retrospective analysis of 464 patients who had undergone surgical resection for EHBD cancer was conducted. Clinicopathological factors likely to influence survival were assessed using univariate and multivariate analysis.

Results

One hundred twenty-four patients had MPDM which included invasive carcinoma (IC) (n =85) and carcinoma in situ (CIS)/ high-grade dysplasia (HGD) (n = 39). The median survival (MS) of R0, R1 as CIS/ HGD, and R1 as IC were 41 months, 29 months, and 18 months, respectively. Adverse prognostic factors were ‘IC’ on the resection margin [HR = 1.66, 95% confidence intervals (CIs) 1.06–2.59, P = 0.026], and no use of adjuvant chemoradiotherapy (HR = 1.57, 95% CIs 1.04–2.39, P = 0.033). Adjuvant chemoradiotherapy was beneficial in patients with MPDM as IC (5-year survival rate 19.7 compared with 2.8%, P = 0.011).

Conclusions

The presence of MPDM is an important prognostic factor in EHBD cancer. When a ductal resection margin is positive, discrimination between ‘IC’ and ‘CIS/ HGD’ is important.

Introduction

A surgical resection has been the mainstay of curative treatment for extrahepatic bile duct (EHBD) cancer. Overall, 5-year survival rates (5YSR) of 20–35% have been reported after resection of EHBD cancer.13 In addition, most patients who undergo a resection die of local tumour recurrence.4,5 This is because a complete surgical resection with tumour-free histological margins is difficult to obtain.

Anatomically, EHBD cancers are classified as perihilar and distal bile duct cancers.4 However, tumours are rarely confined to the short segment as bile duct cancer tends to longitudinally spread along the bile duct wall.6,7 Recent advances in imaging modalities and surgical strategies have improved the outcome of the surgical treatment for EHBD cancer. A surgical resection for EHBD cancer is determined by the location and extent of the tumour.3,613

Although a pre-operative diagnosis for the extension of EHBD cancer has improved in recent years, it is difficult to decide the surgical resection margin pre-operatively.13,14 In some patients, a margin positive resection was inevitable considering the operative risk. A positive resection margin has been considered an adverse prognostic factor;6,1524 however, the reported incidence of a positive surgical resection margin in patients who have undergone a resection with curative intent has varied from 9% to as high as 74%.20,24,25 This could be explained by a variation between institutions or investigators on the principle of the operation or the definition of a positive resection margin. However, there are few reports on the long-term outcome and factor analysis associated with survival in patients with a positive resection margin.

The purpose of this retrospective study was to analyse the clinicopathological features of EHBD cancer with a microscopic positive ductal margin (MPDM) after a surgical resection, and to explore the prognostic factors in patients with EHBD cancer with MPDM. The clarification of whether residual carcinoma in situ (CIS)/high-grade dysplasia (HGD) at ductal resection margins differs prognostically from residual invasive ductal disease in patients with EHBD cancer was also assessed.

Patients and methods

Patients and surgical procedures

With the approval from the institutional review board, all patients with EHBD cancer who underwent a resection at Seoul National University Hospital (SNUH) were entered into a prospectively maintained database between 1995 and 2007.

Pre-operatively, the predominant location of the tumour and the extent of the tumour along the biliary tract were evaluated using imaging studies, including an enhanced computed tomography (CT) scan, ultrasonography, magnetic resonance imaging (MRI), cholangiography and sometimes choledochoscopy. Surgical procedures were decided by each attending surgeon with consideration of the balance between the tumour extent and the safety of each procedure. Distant metastasis, extensive lymph node metastasis such as para-aortic lymph node involvement, bilateral extensive intrahepatic duct infiltration, involvement of major vessels except focal portal vein invasion and other systemic poor operative risk factors were contraindications of a curative resection.

After a laparotomy and the exclusion of distant metastasis, all of the following surgical procedures including a regional lymphadenectomy at the right side of the celiac artery, and all tissues in the hepatoduodenal ligament except the portal vein and the hepatic artery, were removed (skeletonization of the hepatoduodenal ligament).6 The type of resection was determined by the location and extent of the tumour. In patients with localized bile duct cancer in the hepatoduodenal ligament, an EHBD resection (BDR) was adopted, especially in patients in a poor general health condition or with high-risk factors. As the tumour was mainly located in the perihilar bile duct or involved in the liver parenchyma, unilateral hepatic artery, or portal vein, an extended hemihepatectomy including caudate lobectomy combined with bile duct resection (HBR) was performed.6 When the tumour was chiefly located in the distal bile duct, a pancreatoduodenectomy (PD) was usually performed. Since 1991, pylorus preservation has been attempted in all patients undergoing PD, except when duodenal ischaemia, duodenal ulcer or duodenal tumor infiltration was present. A hepatopancreatoduodenectomy (HPD) was indicated in patients with diffuse bile duct cancer.6

Diagnosis and definition of surgical margins

A R0 resection was defined as no residual ductal disease. Intra-operative evaluation of the proximal (hepatic)-side and/or distal (duodenal)-side ductal margins was performed using frozen sections among all patients. Operative specimens were submitted for permanent histopathology. On the basis of the type of resection procedure performed, the appropriate proximal and distal bile duct margins were identified, and a cross-section of each was submitted for histology. When the distal-side ductal margin was positive, additional resection of the intra-pancreatic bile duct or PD was performed, as far as possible in principle. When the proximal-side ductal margin was positive, additional resection of the hepatic duct or an additional hepatectomy was performed where possible. Positive surgical margins were classified into two categories: ‘invasive carcinoma (IC)’and ‘CIS/ HGD’. In the present study, HGD was included in the category of CIS owing to the extreme difficulty if distinguishing between the two epithelial lesions.20 Radial margins were defined as surgical margins other than the ductal margins of the resected specimen, but there were no isolated positive radial margins without MPDM. Microscopic positive ductal margins were confirmed by permanent pathological examination of a resected margin.

Comparison of clinicopathological variables in patients with MPDM and patients follow- up

Resected specimens were submitted to the Department of Pathology in SNUH for histological evaluation, in which experienced hepatobiliary pathologists examined all the specimens without knowledge of any previous diagnoses and clinical details. Clinicopathological variables including age, gender, location of a positive margin, histological grade and type of patient with MPDM were evaluated. Histological findings were described in accordance with the 7th edition TNM staging of the American Joint Committee on Cancer (AJCC).26

Patients were followed regularly in outpatient clinics every 3–6 months, and the information during follow-up for all patients was obtained. The sites of initial disease recurrence were determined from cross-sectional imaging studies, such as computed tomography or magnetic resonance imaging. They were classified as local disease recurrence (resection margin, bilioenteric anastomosis, or porta hepatis), regional disease recurrence (retroperitoneal lymph nodes) and distant disease recurrence (intrahepatic, peritoneum, or extra-abdominal sites). The overall survival was analysed from the date of surgical resection to the date of death from all causes. The causes of death were determined from the medical records. The follow-up period was defined as the intervals between the date of surgical resection and that of the last follow-up.

Adjuvant treatment

Other than for poor performance status or refusal to the chemo- or chemoradiation, adjuvant treatment was performed after the patients were informed of the prognosis and of the effects of each treatment modality. Decisions were made after thorough discussions with patients, physicians and each attending surgeon.

Fluorouracil (5-FU)-based concomitant chemo-radiotherapy (CCRT) consisted of up to 40 Gy at 2 Gy/fraction with a 2-week planned rest, and an intravenous bolus of 5-FU (500 mg/m2/day) given on day 1 to 3 of each split course.27 Some patients received 5-FU monthly for 1 year after radiotherapy.28 In patients treated with chemotherapy alone, various fluoropyrimidines including 5-FU, S-1, capecitabine or uracil-tegafur were used.28

Statistical analysis

The data was analysed using SPSS® version 19.0 (SPSS Inc., Chicago, IL, USA). Continuous and normally distributed variables are presented as the medians and range. Continuous parameters in each group were compared using the independent t-test or the Mann–Whitney U-test, and categorical parameters using the χ2 test or Fisher's exact test. Medical records and survival data were obtained for all patients. Survival curves were constructed using the Kaplan–Meier method and differences in survival were evaluated using the log-rank test. Multivariate analysis for prognostic factors used Cox's proportional hazards model. Probability (P)-values of 0.05 or less were considered statistically significant.

Results

Clinicopathological analysis of EHBD cancer with curative-intended resection

The clinicopathological findings in patients with EHBD cancer with a curative-intended resection are listed in Table 1.

Table 1.

Patients characteristics after a curative intended resection

Characteristics Tumour location Total (n = 464) P-value

Perihilar (n = 208) Distal (n = 246) Diffuse (n = 10)
Age (years) 61.3 ± 10.7 62.9 ± 8.9 61.3 ± 7.5 62.2 ± 9.7 0.243

Gender (M : F) 154:54 175:71 6:4 335:129 0.541

Margin status

negative/ positive (%) 118/90 (43.3) 216/30 (12.2) 6/4 (40.0) 340/124 (26.9) <0.001

Histological grade PP +WD/ MD + PLD 44:147 44:186 2:7 90:340 0.828

Operation type (n, %) <0.001

 HBR 118 (56.7) 0 0 118 (25.4)

 BDR 67 (32.2) 11 (4.5) 2 (20.0) 80 (17.2)

 PD 14 (6.7) 234 (95.1) 7 (70.0) 255 (55.0)

 HPD 9 (4.3) 1 (0.4) 1 (10.0) 11 (2.4)

Median follow-up (months) 29.0 (range 0–163.5) 38 (range 0–181.0) 22.0 (range 2.0–63.0) 32.0 (range 0–181.0) <0.001

PP, papillary carcinoma; WD, well- differentiated; MD, moderate- differentiated; PLD, poorly- differentiated carcinoma; HBR, extended hemihepatectomy combined with bile duct resection; BDR, EHBD resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD, hepatopancreatoduodenectomy.

Clinicopathological analysis of EHBD cancer with MPDM

A total of 124 patients were identified for MPDM after reviewing the pathological diagnosis of resected margin, the results of which are shown in Table 2.

Table 2.

Patients characteristics of a microscopic positive ductal margin among a curative intended resection

Characteristics Tumour location Total (n = 124) P value

Perihilar (n = 90) Distal (n = 30) Diffuse (n = 4)
Age (years) 62.3 ± 10.5 65.7 ± 8.3 62.8 ± 7.8 63.1 ± 10.0 0.343

Gender (M : F) 64:26 19:11 1:3 84:40 0.130

Location of margin (+) PRM/ DRM/ Both/ RM a57/5/28/5 30/0/0/0 3/0/1/0 85/5/29/5 0.004

Histological Grade PP +WD/ MD + PLD 24:60 6:21 1:2 31:83 0.789

Op type (n, %) <0.001

 HBR 39 (43.3) 0 0 39 (31.5)

 BDR 41 (45.6) 2 (6.7) 1 (25.0) 44 (35.5)

 PD 6 (6.7) 28 (93.3) 2 (50.0) 36 (29.0)

 HPD 4 (4.4) 0 1 (25.0) 5 (4.0)

Median follow-up (months) 21 (1.0–163.0) 18 (0–172.6) 9 (4.0–36.0) 20 (0–172.6) 0.380
a

Five of PRM (+) among patients with perihilar bile duct cancer were revealed as combined radial margin positivity.

PRM, proximal resection margin; DRM, distal resection margin; RM, radial resection margin; PP, papillary carcinoma; WD, well- differentiated; MD, moderate- differentiated; PLD, poorly-differentiated carcinoma; HBR, extended hemihepatectomy combined with bile duct resection; BDR, EHBD resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD, hepatopancreatoduodenectomy.

Survival analysis of EHBD cancer with MPDM

The median survival (MS) and 5-year survival rate (5YSR) of R0, R1 as CIS/ HGD, and R1 as IC were 41 months and 44.5%, 29 months and 20.7%, and 18 months and 12.0%, respectively (Fig. 1).

Figure 1.

Figure 1

Overall survival in patients with extrahepatic bile duct cancer with curative intended resection. IC, invasive carcinoma; CIS, carcinoma in situ; HGD, high-grade dysplasia

In the univariate analysis, the outcome after a surgical resection was better in patients with a ‘CIS/HGD’ ductal margin than in those with a ‘IC’ ductal margin (Table 3 and Fig. 1). Age 60 years or older, lymph node metastasis (N stage) and no use of adjuvant treatment including CCRT had a marginally significant adverse effect on survival (Table 3).

Table 3.

Survival analysis of microscopic positive ductal margin (MPDM) among a curative intended resection in patients with extrahepatic bile duct (EHBD) cancer

Variable No. of patients Median survival (months) P-value
Age <60/≥60 38/86 23 (1.0–163.0)/20 (1.0–172.0) 0.069

Gender Male/Female 84/40 25 (0–163.5)/18 (3.0–172.6) 0.307

aT stage T1/T2/T3 19/53/52 29 (1.0–123.0)/20 (3.0–143.7)/18 (0–172.6) 0.657

aN stage N0/N1 89/35 25 (1.0–172.6)/16 (0–163.5) 0.097

Tumour location Perihilar/Distal/Diffuse 90/30/4 21 (1.0–163.5)/18 (0–172.6)/9 (4.0–36.0) 0.475

bDifferentiation PP + WD/MD + PLD 33/86 32 (0–151.0)/18 (1.0–172.6) 0.246

Perineural invasion Not identified/Present 41/83 36 (1.0–72.9)/20 (0–172.6) 0.216

Resection margin IC/CIS + HG 85/39 18 (0–172.6)/29 (1.0–151.0) 0.029

Type of operation HBR/BDR/PD/HPD 39/44/36/5 20 (1.0–163.5)/25 (3.0–143.7)/23 (0–172.6)/13 (2.0–40.0) 0.264

Adjuvant treatment No/Yes 54/70 18 (0–151.0)/21 (4.0–172.6) 0.078

 Chemotherapy alone No/Yes 54/6 18 (2.0–72.9)/16 (4.0–172.6) 0.866

 CCRT No/Yes 61/63 18 (2.0–64.0)/21 (5.0–163.5) 0.065

Values in parenthesis are range of follow-up.

a

AJCC 7th edition.

b

The pathological reports of five patients did not contain the histological differentiation.

PP, papillary carcinoma; WD, well-differentiated; MD, moderate-differentiated; PLD, poorly-differentiated carcinoma; HBR, extended hemihepatectomy combined with bile duct resection; BDR, EHBD resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD, hepatopancreatoduodenectomy; CCRT, concomitant chemo-radiotherapy.

After multivariate analysis, there were two independent adverse prognostic factors: invasive carcinoma on the resection margin [hazard ratio (HR) = 1.66, 95% confidence intervals 1.06–2.59, P = 0.026] and no use of adjuvant CCRT (HR = 1.57, 95% confidence intervals 1.04–2.39, P = 0.033).

Ductal margin status and recurrence

Fifty-three with IC and 25 out of 124 patients with CIS/ HGD had disease recurrence during follow-up. There were no significant differences in local disease recurrence (25 of 85 patients, versus 14 of 39 patients, P = 0.820), regional disease recurrence (9 of 85 patients versus 6 of 39 patients, P = 0.629), distant disease recurrence (31 of 85 patients versus 15 of 39 patients, P = 0.616) between IC and CIS/ HGD.

Natural course of MPDM

Figure 2 shows the clinical course of patients with MPDM. As previously noted, the 5YSR of CIS/HGD was higher than that of IC (Table 3 and Fig. 1). In addition, the disease-free (DF) (5YSR) of the CIS/HGD group was higher than that of the IC group with a statistically marginal significance. When subdividing the IC group as treated adjuvant treatment including or excluding CCRT, the 5YSR and DF-5YSR of the patients with adjuvant treatment were higher than that without adjuvant treatment (5YSR 19.7 versus 2.8%, P = 0.011; DF-5YSR 16.6 versus 0%, P = 0.012) (Fig. 2).

Figure 2.

Figure 2

Clinical course of patients with microscopic positive ductal margin. 5YSR, 5-year survival rate; DF-5YSR, disease-free 5-year survival rate

Discussion

The most consistent independent determinant for long-term survival after a potentially curative resection of EHBD cancer is the surgical margin status of the resected bile duct. In consideration of a few studies insisting that the presence of MPDM may not have an effect on the overall mean survival,29 numerous studies have reported an association of MPDM with a major decrease in survival rates and an increase in recurrence rates.6,15,1821,24 This present study added MPDM as an adverse prognostic factor (Fig. 1).

There are several reports showing some patients undergoing a resection with microscopic tumour involvement at the bile duct margin survive longer than expected.6,11,20,30,31 Among these, several studies reported CIS/HGD at the bile duct margin was prognostically better than residual IC in patients undergoing surgical resection for EHBD cancer.12,20,30,32,33 However, there are few studies on the long-term fate and on detailed analysis for factor associated survival in patients with a positive resection margin. In the present study, in spite of concerns about a significant correlation with IC and other features of tumour extension, IC on the resection margin was revealed as one of the independent prognostic factors after multivariate analysis. This can be explained by the biological nature of the main tumours displaying extensive superficial spread, which is likely to be responsible for the remnant CIS/HGD at the bile duct stump, tends to be less malignant compared with that of a conventional IC.33

In spite of the slower growth, remnant CIS/HGD has the potential to develop into lethal IC. In this study, regardless of the prolonged survival compared to MPDM as IC, survival of MPDM as CIS/HGD had a worse prognosis than that of the R0 resection (Fig. 1). Thus, CIS/HGD should be completely resected to achieve long-term survival if possible. However, when CIS/ HGD spreads too widely, extended surgery such as HPD may be required. For patients in a poor general condition or with high operative risk, limited resection of the main invasive cancer with CIS/HGD remaining at the ductal stumps, as an alternative procedure, might bring considerable survival benefits.

Many other clinicopathological factors have been reported to have a positive or negative impact on survival, including lymph node metastasis,6,15,23,25,34 AJCC pT,34 histopathological grading6,8 and gender35 in resected EHBD cancer. In this study, there were no significant differences with respect to survival based on the location of the tumour or resection type, suggesting that once the microscopic remnant tumour has occurred, the prognoses of different locational types are similar (Table 3). These results were similar to Jang et al. 6 where they reported on the actual long-term outcome of EHBD cancer after a surgical resection.

There has been controversy whether remnant CIS/HGD at the bile duct stump develops into IC. Jang et al. 6 previously reported that, in attempted curative surgery, microscopic tumor involvement in the resection margin did not always mean early recurrence. However, there are several reports that show a significant relationship between local recurrence and ductal margin status.12,20,30,32,33 Furthermore, some studies suggested residual CIS may cause late local disease recurrences, whereas residual invasive ductal lesions cause early local recurrences.20,36 In this study, 14 out of 39 patients with CIS/HGD showed local recurrence at the bile duct stump, such as, bilioenteric anastomosis, or porta hepatis. However, this result did not have any statistical difference in the local recurrence rate in patients with IC (25 out of 85 patients, P = 0.820). As a result, it could be possible that CIS/HGD has the potential to progress to IC.

Even although there is a possibility for CIS/HGD to develop into IC, there are differences in their biological behaviours. Remnant CIS/HGD is likely to develop into IC in the late phase after surgery. In this study, the DF-5YSR of the CIS/HGD group was significantly higher than that of the IC group (Fig. 2), suggesting that CIS/ HGD had less malignancy and showed slower growth than IC. In spite of the similar incidence of recurrence, it is noteworthy that a ductal margin with CIS/ HGD resulted in a prolonged disease-free survival than that of a ductal margin with IC. Therefore, as mentioned above, for patients in a poor general condition or with high operative risk, limited resection of the main invasive cancer with CIS/HGD remaining at the ductal stumps, as an alternative procedure, may bring considerable survival benefits.37

Gawk et al. 31 suggested that adjuvant radiotherapy might be useful in patients with EHBD cancer, especially for those patients with microscopic residual tumours and positive lymph nodes after resection for increasing local control In this study, there was no survival benefit with adjuvant chemotherapy alone but an increase in survival in patients with MPDM who received CCRT with marginal significance (Table 3), especially the patients with an IC resection margin (Fig. 2). In spite of this study has the limitation that the post-operative adjuvant treatment was given to selected patients and the treatment regimens differed significantly among the individuals, some subsets of patients with a positive margin could have a better prognosis if chemoradiotherapy is combined with a surgical resection.6,10,31

In conclusion, among patients undergoing a surgical resection for EHBD cancer, IC at the ductal resection margins appears to have a more adverse effect on survival, whereas residual CIS or HGD does not. It is therefore clear that when the ductal resection margin status is positive upon pathological examination, discrimination between CIS/ HGD and IC is clinically important, and a resection should be considered and efforts should be made to obtain an IC-free margin. For MPDM, especially IC, adjuvant chemoradiation can be beneficial.

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (No. 1120310).

Conflicts of interest

The authors have no conflicts to disclose.

References

  • 1.Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250:210–218. doi: 10.1097/SLA.0b013e3181afe0ab. [DOI] [PubMed] [Google Scholar]
  • 2.van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven GJ, Lameris JS, et al. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37:65–71. doi: 10.1016/j.ejso.2010.11.008. [DOI] [PubMed] [Google Scholar]
  • 3.DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–762. doi: 10.1097/01.sla.0000251366.62632.d3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int. 2011;10:10–20. doi: 10.1016/s1499-3872(11)60001-5. [DOI] [PubMed] [Google Scholar]
  • 5.Bengmark S, Ekberg H, Evander A, Klofver-Stahl B, Tranberg KG. Major liver resection for hilar cholangiocarcinoma. Ann Surg. 1988;207:120–125. doi: 10.1097/00000658-198802000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77–84. doi: 10.1097/01.sla.0000150166.94732.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sakamoto Y, Nara S, Kishi Y, Esaki M, Shimada K, Kokudo N, et al. Is extended hemihepatectomy plus pancreaticoduodenectomy justified for advanced bile duct cancer and gallbladder cancer? Surgery. 2013;153:794–800. doi: 10.1016/j.surg.2012.11.024. [DOI] [PubMed] [Google Scholar]
  • 8.Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240:95–101. doi: 10.1097/01.sla.0000129491.43855.6b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Choi SB, Park SW, Kim KS, Choi JS, Lee WJ. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol. 2009;99:335–342. doi: 10.1002/jso.21238. [DOI] [PubMed] [Google Scholar]
  • 10.Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002;54:414–419. doi: 10.1016/s0360-3016(02)02952-8. [DOI] [PubMed] [Google Scholar]
  • 11.Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137:396–402. doi: 10.1016/j.surg.2004.10.008. [DOI] [PubMed] [Google Scholar]
  • 12.Sakamoto Y, Shimada K, Nara S, Esaki M, Ojima H, Sano T, et al. Surgical management of infrahilar/suprapancreatic cholangiocarcinoma: an analysis of the surgical procedures, surgical margins, and survivals of 77 patients. J Gastrointest Surg. 2010;14:335–343. doi: 10.1007/s11605-009-1072-7. [DOI] [PubMed] [Google Scholar]
  • 13.Fukami Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Salvage hepatectomy for perihilar malignancy treated initially with biliary self-expanding metallic stents. Surgery. 2013;153:627–633. doi: 10.1016/j.surg.2012.11.008. [DOI] [PubMed] [Google Scholar]
  • 14.Seo H, Lee JM, Kim IH, Han JK, Kim SH, Jang JY, et al. Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr. 2009;33:376–382. doi: 10.1097/RCT.0b013e318184f3f7. [DOI] [PubMed] [Google Scholar]
  • 15.Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256–1263. doi: 10.1007/s00268-007-9001-y. [DOI] [PubMed] [Google Scholar]
  • 16.Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg. 2006;93:1488–1494. doi: 10.1002/bjs.5482. [DOI] [PubMed] [Google Scholar]
  • 17.Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol. 2005;31:533–539. doi: 10.1016/j.ejso.2005.02.021. [DOI] [PubMed] [Google Scholar]
  • 18.Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol. 2007;33:202–207. doi: 10.1016/j.ejso.2006.09.033. [DOI] [PubMed] [Google Scholar]
  • 19.Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, et al. Surgical treatment of hilar cholangiocarcinoma in the ‘new era’: the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17:449–454. doi: 10.1007/s00534-009-0209-0. [DOI] [PubMed] [Google Scholar]
  • 20.Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103:1210–1216. doi: 10.1002/cncr.20906. [DOI] [PubMed] [Google Scholar]
  • 21.Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, et al. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg. 2009;249:296–302. doi: 10.1097/SLA.0b013e318190a647. [DOI] [PubMed] [Google Scholar]
  • 22.Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005;241:693–699. doi: 10.1097/01.sla.0000160701.38945.82. discussion 699–702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg. 2002;137:69–73. doi: 10.1001/archsurg.137.1.69. [DOI] [PubMed] [Google Scholar]
  • 24.Cannon RM, Brock G, Buell JF. Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB. 2012;14:142–149. doi: 10.1111/j.1477-2574.2011.00419.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg. 2003;238:84–92. doi: 10.1097/01.SLA.0000074984.83031.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Andy Trotty I. American Joint Committee on Cancer Staging Manual. 7th edn. New York: Springer-Verlag; 2010. [Google Scholar]
  • 27.Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, et al. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol. 2012;35:136–140. doi: 10.1097/COC.0b013e318209aa29. [DOI] [PubMed] [Google Scholar]
  • 28.Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer. 2008;8:374. doi: 10.1186/1471-2407-8-374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hernandez J, Cowgill SM, Al-Saadi S, Villadolid D, Ross S, Kraemer E, et al. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol. 2008;15:807–814. doi: 10.1245/s10434-007-9756-2. [DOI] [PubMed] [Google Scholar]
  • 30.Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 2007;31:1788–1796. doi: 10.1007/s00268-007-9102-7. [DOI] [PubMed] [Google Scholar]
  • 31.Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010;78:194–198. doi: 10.1016/j.ijrobp.2009.07.003. [DOI] [PubMed] [Google Scholar]
  • 32.Endo I, House MG, Klimstra DS, Gonen M, D'Angelica M, Dematteo RP, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:2104–2112. doi: 10.1245/s10434-008-0003-2. [DOI] [PubMed] [Google Scholar]
  • 33.Nakanishi Y, Kondo S, Zen Y, Yonemori A, Kubota K, Kawakami H, et al. Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci. 2010;17:166–173. doi: 10.1007/s00534-009-0127-1. [DOI] [PubMed] [Google Scholar]
  • 34.Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, et al. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:463–469. doi: 10.1007/s00534-009-0206-3. [DOI] [PubMed] [Google Scholar]
  • 35.Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg. 2004;139:514–523. doi: 10.1001/archsurg.139.5.514. discussion 523–515. [DOI] [PubMed] [Google Scholar]
  • 36.Nakanishi Y, Zen Y, Kawakami H, Kubota K, Itoh T, Hirano S, et al. Extrahepatic bile duct carcinoma with extensive intraepithelial spread: a clinicopathological study of 21 cases. Mod Pathol. 2008;21:807–816. doi: 10.1038/modpathol.2008.65. [DOI] [PubMed] [Google Scholar]
  • 37.Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, et al. Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB. 2011;13:139–147. doi: 10.1111/j.1477-2574.2010.00262.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from HPB : The Official Journal of the International Hepato Pancreato Biliary Association are provided here courtesy of Elsevier

RESOURCES